Rapport Therapeutics’ $436.1 Million in Liquidity Is Expected to Last Through 2029

Key Facts

I found no confirmation of a share and debt offering totaling $350 million in the official public sources I reviewed, and no available company announcement verifies the amounts or type of securities described in the earlier draft. In a previous filing, Rapport Therapeutics said it had $436.1 million in cash, cash equivalents and short-term investments as of June 30, 2026, excluding restricted cash. The company estimated that this balance would fund operations through the second half of 2029. The alleged offering or the intended use of its proceeds therefore cannot be presented as a confirmed fact. RAPP shares closed at $25.33 on October 26, 2026, according to data provided by EL7.

The liquidity reported at the end of June offers a picture of the company’s available resources before any alleged offering, but does not establish that it raised new funding or needed to do so. The company said the $436.1 million includes cash, cash equivalents and short-term investments, excluding restricted cash. It said the balance would fund operations through the second half of 2029, its stated estimate of its cash runway. The use of proceeds described in the draft has not been confirmed, whether to cover operations or develop clinical programs. The company also had net proceeds of about $269.4 million from its September 2025 public offering, after deducting discounts and commissions and offering expenses, according to its annual report filed with the U.S. Securities and Exchange Commission.

One of the company’s development programs centers on RAP-219 for acute mania in bipolar I disorder. The randomized, double-blind, placebo-controlled Phase 2 trial included 253 adults in the United States, according to the company. Rapport plans to meet with the U.S. Food and Drug Administration in the first quarter of 2027 to discuss Phase 2 data and the design of registration trials for the drug. The company said the start of two Phase 3 trials for bipolar mania is expected in the second half of 2027. These dates represent the next steps the company has announced for the RAP-219 program, with no filing establishing a link to new funding.

In another program for the drug, the company said its pivotal Phase 3 FOCUS 1 and FOCUS 2 trials for focal-onset seizures are enrolling. The filing places this activity alongside announced plans for two Phase 3 trials in bipolar mania and the planned meeting with the FDA in the first quarter of 2027. The company expects the mania trials to start in the second half of that year. These dates remain company expectations and plans, while no official public confirmation was found for the dual offering described in the draft. The intended use of proceeds from that alleged offering has also not been established.